{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:50:14Z","timestamp":1772085014730,"version":"3.50.1"},"reference-count":52,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>\n                      The phase 3 study Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First; NCT02668653) demonstrated improved overall survival (OS) in newly diagnosed patients with FMS-like tyrosine kinase 3 (\n                      <jats:italic>FLT3<\/jats:italic>\n                      ) internal tandem duplication\u2013positive AML treated with the FLT3 inhibitor quizartinib over placebo, leading to the approval of quizartinib in this population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>\n                      To describe the bridging study between the Navigate clinical trial assay (CTA) used for patient selection in QuANTUM-First and the LeukoStrat CDx [companion diagnostic]\n                      <jats:italic>FLT3<\/jats:italic>\n                      Mutation Assay, necessary to establish concordance between these 2 assays to support the QuANTUM-First supplemental premarket application for the CDx.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>\n                      Assay agreement was established if lower bounds of the 95% CI for both positive and negative percentage agreement were 90% or greater. Treatment efficacy was evaluated to assess if OS in the intent-to-treat (ITT) CDx\n                      <jats:sup>+<\/jats:sup>\n                      population (CTA\n                      <jats:sup>+<\/jats:sup>\n                      , CDx\n                      <jats:sup>+<\/jats:sup>\n                      ) and the QuANTUM-First ITT were comparable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>\n                      The lower bounds of the 95% CI were greater than 90% for positive percentage agreement (94.7%) and negative percentage agreement (100%) based on results from 1029 patients, demonstrating agreement between CTA and CDx. The OS benefit provided by quizartinib in the ITT CDx\n                      <jats:sup>+<\/jats:sup>\n                      population in the bridging study, with a median OS of 29.4 months for quizartinib versus 14.8 months for placebo (hazard ratio, 0.794; 2-sided stratified log-rank\n                      <jats:italic>P<\/jats:italic>\n                      = .06), was comparable with the OS benefit in the QuANTUM-First ITT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>\n                      The LeukoStrat CDx\n                      <jats:italic>FLT3<\/jats:italic>\n                      Mutation Assay aids in selecting newly diagnosed patients with\n                      <jats:italic>FLT3<\/jats:italic>\n                      internal tandem duplication\u2013positive AML for quizartinib therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2024-0449-oa","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T14:51:03Z","timestamp":1756824663000},"page":"235-243","source":"Crossref","is-referenced-by-count":0,"title":["QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3\u2013Internal Tandem Duplications for Treatment With Quizartinib"],"prefix":"10.5858","volume":"150","author":[{"given":"Jaime E.","family":"Connolly Rohrbach","sequence":"first","affiliation":[{"name":"From Global Oncology R&D (Connolly Rohrbach, Kamel, Khambata-Ford), Clinical Biomarkers (Chang), and Biostatistics (Karnoub, Liu), Daiichi Sankyo, Inc., Basking Ridge, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken C. N.","family":"Chang","sequence":"additional","affiliation":[{"name":"From Global Oncology R&D (Connolly Rohrbach, Kamel, Khambata-Ford), Clinical Biomarkers (Chang), and Biostatistics (Karnoub, Liu), Daiichi Sankyo, Inc., Basking Ridge, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Karnoub","sequence":"additional","affiliation":[{"name":"From Global Oncology R&D (Connolly Rohrbach, Kamel, Khambata-Ford), Clinical Biomarkers (Chang), and Biostatistics (Karnoub, Liu), Daiichi Sankyo, Inc., Basking Ridge, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"From Global Oncology R&D (Connolly Rohrbach, Kamel, Khambata-Ford), Clinical Biomarkers (Chang), and Biostatistics (Karnoub, Liu), Daiichi Sankyo, Inc., Basking Ridge, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasser Mostafa","family":"Kamel","sequence":"additional","affiliation":[{"name":"From Global Oncology R&D (Connolly Rohrbach, Kamel, Khambata-Ford), Clinical Biomarkers (Chang), and Biostatistics (Karnoub, Liu), Daiichi Sankyo, Inc., Basking Ridge, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirin","family":"Khambata-Ford","sequence":"additional","affiliation":[{"name":"From Global Oncology R&D (Connolly Rohrbach, Kamel, Khambata-Ford), Clinical Biomarkers (Chang), and Biostatistics (Karnoub, Liu), Daiichi Sankyo, Inc., Basking Ridge, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn","family":"Rivera","sequence":"additional","affiliation":[{"name":"Navigate BioPharma Services, Inc., Carlsbad, California (Rivera, Lameh)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelveh","family":"Lameh","sequence":"additional","affiliation":[{"name":"Navigate BioPharma Services, Inc., Carlsbad, California (Rivera, Lameh)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Rudenko","sequence":"additional","affiliation":[{"name":"Biostatistics (Rudenko), Clinical Laboratory Operations (Thornes), Regulatory Affairs (Todt), Global Regulatory, Quality & Clinical Affairs (Gerhold), Product Development (Huang), and CEO (Miller), Invivoscribe, Inc., San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Thornes","sequence":"additional","affiliation":[{"name":"Biostatistics (Rudenko), Clinical Laboratory Operations (Thornes), Regulatory Affairs (Todt), Global Regulatory, Quality & Clinical Affairs (Gerhold), Product Development (Huang), and CEO (Miller), Invivoscribe, Inc., San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Todt","sequence":"additional","affiliation":[{"name":"Biostatistics (Rudenko), Clinical Laboratory Operations (Thornes), Regulatory Affairs (Todt), Global Regulatory, Quality & Clinical Affairs (Gerhold), Product Development (Huang), and CEO (Miller), Invivoscribe, Inc., San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Gerhold","sequence":"additional","affiliation":[{"name":"Biostatistics (Rudenko), Clinical Laboratory Operations (Thornes), Regulatory Affairs (Todt), Global Regulatory, Quality & Clinical Affairs (Gerhold), Product Development (Huang), and CEO (Miller), Invivoscribe, Inc., San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[{"name":"Biostatistics (Rudenko), Clinical Laboratory Operations (Thornes), Regulatory Affairs (Todt), Global Regulatory, Quality & Clinical Affairs (Gerhold), Product Development (Huang), and CEO (Miller), Invivoscribe, Inc., San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey E.","family":"Miller","sequence":"additional","affiliation":[{"name":"Biostatistics (Rudenko), Clinical Laboratory Operations (Thornes), Regulatory Affairs (Todt), Global Regulatory, Quality & Clinical Affairs (Gerhold), Product Development (Huang), and CEO (Miller), Invivoscribe, Inc., San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander E.","family":"Perl","sequence":"additional","affiliation":[{"name":"the Division of Hematology\/Oncology, University of Pennsylvania, Philadelphia (Perl)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Levis","sequence":"additional","affiliation":[{"name":"the Division of Hematologic Malignancies, Johns Hopkins University, Baltimore, Maryland (Levis)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Ito","sequence":"additional","affiliation":[{"name":"Global Companion Diagnostics, Daiichi Sankyo Co., Ltd., Tokyo, Japan (Ito)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","reference":[{"key":"i1543-2165-150-3-235-b01","series-title":"Hematology Am Soc Hematol Educ Program","first-page":"220","article-title":"FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013","volume":"2013","author":"Levis","year":"2013","unstructured":"Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology Am Soc Hematol Educ Program. 2013;2013:220\u2013226."},{"issue":"6","key":"i1543-2165-150-3-235-b02","series-title":"Blood","first-page":"1752","article-title":"The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials","volume":"98","author":"Kottaridis","year":"2001","unstructured":"Kottaridis PD,\nGale RE,\nFrew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752\u20131759."},{"issue":"10388","key":"i1543-2165-150-3-235-b03","series-title":"Lancet","first-page":"1571","article-title":"on behalf of the QuANTUM-First Study Group. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","unstructured":"Erba HP,\nMontesinos P,\nKim HJ, et al.; on behalf of the QuANTUM-First Study Group. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10388):1571\u20131583."},{"key":"i1543-2165-150-3-235-b04","article-title":"VANFLYTA\u00ae first FLT3 inhibitor approved in the U.S. specifically for patients with newly diagnosed FLT3-ITD positive AML [press release]","author":"Daiichi Sankyo","year":"2023","unstructured":"Daiichi Sankyo. VANFLYTA\u00ae first FLT3 inhibitor approved in the U.S. specifically for patients with newly diagnosed FLT3-ITD positive AML [press release]. https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202307\/20230720_E.pdf. Published July 20, 2023. Accessed July 31, 2023."},{"key":"i1543-2165-150-3-235-b05","article-title":"VANFLYTA\u00ae (quizartinib) [package insert]","year":"2024","unstructured":"VANFLYTA\u00ae (quizartinib) [package insert]. Daiichi Sankyo, Inc. https:\/\/daiichisankyo.us\/prescribing-information-portlet\/getPIContent?productName=Vanflyta&inline=true. Published June 2024. Accessed August 8, 2025."},{"key":"i1543-2165-150-3-235-b06","article-title":"VANFLYTA\u00ae first FLT3 inhibitor approved in Japan for patients with newly diagnosed FLT3-ITD positive AML [press release]","author":"Daiichi Sankyo.","year":"2023","unstructured":"Daiichi Sankyo.VANFLYTA\u00ae first FLT3 inhibitor approved in Japan for patients with newly diagnosed FLT3-ITD positive AML [press release]. https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202305\/20230525_E.pdf. Published May 25, 2023. Accessed June 13, 2023."},{"key":"i1543-2165-150-3-235-b07","article-title":"VANFLYTA\u00ae approved in the EU as the first FLT3 inhibitor specifically for patients with newly diagnosed FLT3-ITD positive AML [press release]","author":"Daiichi Sankyo.","year":"2023","unstructured":"Daiichi Sankyo. VANFLYTA\u00ae approved in the EU as the first FLT3 inhibitor specifically for patients with newly diagnosed FLT3-ITD positive AML [press release]. https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202311\/20231109_E.pdf. Published November 9, 2023. Accessed November 9, 2023."},{"key":"i1543-2165-150-3-235-b08","article-title":"VANFLYTA\u00ae (quizartinib) summary of product characteristics","year":"2023","unstructured":"VANFLYTA\u00ae (quizartinib) summary of product characteristics. Daiichi Sankyo Europe GmbH. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vanflyta-epar-product-information_en.pdf. Published November 2023. Accessed November 9, 2023."},{"key":"i1543-2165-150-3-235-b09","article-title":"Quizartinib approved to treat adult patients with a type of blood cancer","author":"Medicines and Healthcare Products Regulatory Agency.","year":"2024","unstructured":"Medicines and Healthcare Products Regulatory Agency. Quizartinib approved to treat adult patients with a type of blood cancer [press release]. https:\/\/www.gov.uk\/government\/news\/quizartinib-approved-to-treat-adult-patients-with-a-type-of-blood-cancer. Published March 11, 2024. Accessed May 24, 2024."},{"key":"i1543-2165-150-3-235-b10","article-title":"VANFLYTA\u00ae (quizartinib) summary of product characteristics","year":"2024","unstructured":"VANFLYTA\u00ae (quizartinib) summary of product characteristics. Daiichi Sankyo UK Ltd. https:\/\/products.mhra.gov.uk\/substance\/?substance=QUIZARTINIB%20DIHYDROCHLORIDE. Published March 2024. Accessed May 24, 2024."},{"key":"i1543-2165-150-3-235-b11","article-title":"VANFLYTA\u00ae, Filmtabletten (Quizartinibum)","author":"Swiss Agency for Therapeutic Products, Swissmedic.","year":"2025","unstructured":"Swiss Agency for Therapeutic Products, Swissmedic. VANFLYTA\u00ae, Filmtabletten (Quizartinibum). https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/humanarzneimittel\/authorisations\/new-medicines\/vanflyta-filmtabletten-quizartinibum.html. Published March 31, 2025. Accessed April 24, 2025."},{"key":"i1543-2165-150-3-235-b12","article-title":"Invivoscribe announces FDA approval of the LeukoStrat\u00ae CDx FLT3 Mutation Assay to select patients with FLT3-ITD positive AML for treatment with VANFLYTA\u00ae","author":"Invivoscribe","year":"2023","unstructured":"Invivoscribe. Invivoscribe announces FDA approval of the LeukoStrat\u00ae CDx FLT3 Mutation Assay to select patients with FLT3-ITD positive AML for treatment with VANFLYTA\u00ae [press release]. https:\/\/invivoscribe.com\/invivoscribe-announces-fda-approval-of-the-leukostrat-cdx-flt3-mutation-assay-to-select-patients-with-flt3-itd-positive-aml-for-treatment-with-vanflyta\/. Published July 21, 2023. Accessed October 12, 2023."},{"key":"i1543-2165-150-3-235-b13","article-title":"Invivoscribe announces updated reimbursement for the LeukoStrat CDx FLT3 Mutation Assay\u00ae to select newly diagnosed FLT3-ITD positive AML patients eligible for VANFLYTA\u00ae in Japan [press release]","author":"Invivoscribe","year":"2023","unstructured":"Invivoscribe. Invivoscribe announces updated reimbursement for the LeukoStrat CDx FLT3 Mutation Assay\u00ae to select newly diagnosed FLT3-ITD positive AML patients eligible for VANFLYTA\u00ae in Japan [press release]. https:\/\/invivoscribe.com\/invivoscribe-announces-updated-reimbursement-for-the-leukostrat-cdx-flt3-mutation-assay-to-select-newly-diagnosed-flt3-itd-positive-aml-patients-eligible-for-vanflyta-in-japan\/. Published May 25, 2023. Accessed October 12, 2023."},{"key":"i1543-2165-150-3-235-b14","article-title":"EU notified body (BSI Netherlands) and the EMA grant approval of the LeukoStrat\u00ae CDx FLT3 Mutation Assay for VANFLYTA\u00ae therapy in the EU and EEA [press release]","author":"Invivoscribe","year":"2024","unstructured":"Invivoscribe. EU notified body (BSI Netherlands) and the EMA grant approval of the LeukoStrat\u00ae CDx FLT3 Mutation Assay for VANFLYTA\u00ae therapy in the EU and EEA [press release]. https:\/\/invivoscribe.com\/eu-notified-body-bsi-netherlands-and-the-ema-grant-approval-of-the-leukostrat-cdx-flt3-mutation-assay-for-vanflyta-therapy-in-the-eu-and-eea\/. Published October 8, 2024. Accessed October 25, 2024."},{"key":"i1543-2165-150-3-235-b15","article-title":"Invivoscribe announces registration of the LeukoStrat\u00ae CDx FLT3 Mutation Assay in the United Kingdom and Switzerland [press release]","author":"Invivoscribe","year":"2025","unstructured":"Invivoscribe. Invivoscribe announces registration of the LeukoStrat\u00ae CDx FLT3 Mutation Assay in the United Kingdom and Switzerland [press release]. https:\/\/invivoscribe.com\/invivoscribe-announces-registration-of-the-leukostrat-cdx-flt3-mutation-assay-in-the-united-kingdom-and-switzerland\/. Published March 27, 2025. Accessed April 24, 2025."},{"key":"i1543-2165-150-3-235-b16","article-title":"The LeukoStrat\u00ae CDx FLT3 Mutation Assay","author":"Invivoscribe","unstructured":"Invivoscribe. The LeukoStrat\u00ae CDx FLT3 Mutation Assay. https:\/\/invivoscribe.com\/products\/companion-diagnostics-cdx\/. Accessed December 6, 2023."},{"issue":"11","key":"i1543-2165-150-3-235-b17","series-title":"Oncotarget","first-page":"943","article-title":"Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells","volume":"11","author":"Aikawa","year":"2020","unstructured":"Aikawa T,\nTogashi N,\nIwanaga K, et al. Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells. Oncotarget. 2020;11(11):943\u2013955."},{"issue":"7","key":"i1543-2165-150-3-235-b18","series-title":"Blood","first-page":"1425","article-title":"FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML","volume":"115","author":"Pratz","year":"2010","unstructured":"Pratz KW,\nSato T,\nMurphy KM,\nStine A,\nRajkhowa T,\nLevis M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood. 2010;115(7):1425\u20131432."},{"issue":"14","key":"i1543-2165-150-3-235-b19","series-title":"Blood","first-page":"2984","article-title":"AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)","volume":"114","author":"Zarrinkar","year":"2009","unstructured":"Zarrinkar PP,\nGunawardane RN,\nCramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114(14):2984\u20132992."},{"issue":"4","key":"i1543-2165-150-3-235-b20","series-title":"PLoS One","first-page":"e0121177","article-title":"Crystal structure of the FLT3 kinase domain bound to the inhibitor quizartinib (AC220)","volume":"10","author":"Zorn","year":"2015","unstructured":"Zorn JA,\nWang Q,\nFujimura E,\nBarros T,\nKuriyan J. Crystal structure of the FLT3 kinase domain bound to the inhibitor quizartinib (AC220). PLoS One. 2015;10(4):e0121177."},{"issue":"2","key":"i1543-2165-150-3-235-b21","series-title":"J Mol Diagn","first-page":"96","article-title":"Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay","volume":"5","author":"Murphy","year":"2003","unstructured":"Murphy KM,\nLevis M,\nHafez MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. 2003;5(2):96\u2013102."},{"key":"i1543-2165-150-3-235-b22","article-title":"Japan\u2019s MHLW approves Invivoscribe\u2019s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo\u2019s quizartinib for treatment of relapsed\/refractory FLT3-ITD AML: expands use to include specimens collected in EDTA [press release]","author":"Invivoscribe","year":"2019","unstructured":"Invivoscribe. Japan\u2019s MHLW approves Invivoscribe\u2019s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo\u2019s quizartinib for treatment of relapsed\/refractory FLT3-ITD AML: expands use to include specimens collected in EDTA [press release]. https:\/\/invivoscribe.com\/japans-mhlw-approves-invivoscribes-leukostrat-cdx-flt3-mutation-assay-as-the-cdx-for-daiichi-sankyos-quizartinib-for-treatment-of-relapsed-refractory-flt3-itd-aml-expands\/. Published June 19, 2019. Accessed October 12, 2023."},{"issue":"3","key":"i1543-2165-150-3-235-b23","series-title":"R I Med J (2013)","first-page":"38","article-title":"Acute myeloid leukemia: a review","volume":"103","author":"Pelcovits","year":"2020","unstructured":"Pelcovits A,\nNiroula R. Acute myeloid leukemia: a review. R I Med J (2013). 2020;103(3):38\u201340."},{"issue":"9","key":"i1543-2165-150-3-235-b24","series-title":"Cureus","first-page":"e45765","article-title":"FLT3 mutations in acute myeloid leukemia: unraveling the molecular mechanisms and implications for targeted therapies","volume":"15","author":"Jalte","year":"2023","unstructured":"Jalte M,\nAbbassi M,\nEl Mouhi H,\nDaha Belghiti H,\nAhakoud M,\nBekkari H. FLT3 mutations in acute myeloid leukemia: unraveling the molecular mechanisms and implications for targeted therapies. Cureus. 2023;15(9):e45765."},{"key":"i1543-2165-150-3-235-b25","article-title":"ISO 20916:2019: in vitro diagnostic medical devices\u2014clinical performance studies using specimens from human subjects\u2014good study practice","author":"International Organization for Standardization","unstructured":"International Organization for Standardization. ISO 20916:2019: in vitro diagnostic medical devices\u2014clinical performance studies using specimens from human subjects\u2014good study practice. https:\/\/www.iso.org\/standard\/69455.html. Accessed August 8, 2025."},{"key":"i1543-2165-150-3-235-b26","article-title":"ICH E6(R3): Guideline for good clinical practice","author":"International Council for Harmonisation","unstructured":"International Council for Harmonisation. ICH E6(R3): Guideline for good clinical practice. https:\/\/database.ich.org\/sites\/default\/files\/ICH_E6(R3)_Step4_FinalGuideline_2025_0106.pdf. Published January 6, 2025. Accessed August 8, 2025."},{"key":"i1543-2165-150-3-235-b01","series-title":"Hematology Am Soc Hematol Educ Program","first-page":"220","article-title":"FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013","volume":"2013","author":"Levis","year":"2013","unstructured":"Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology Am Soc Hematol Educ Program. 2013;2013:220\u2013226."},{"issue":"6","key":"i1543-2165-150-3-235-b02","series-title":"Blood","first-page":"1752","article-title":"The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials","volume":"98","author":"Kottaridis","year":"2001","unstructured":"Kottaridis PD,\nGale RE,\nFrew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752\u20131759."},{"issue":"10388","key":"i1543-2165-150-3-235-b03","series-title":"Lancet","first-page":"1571","article-title":"on behalf of the QuANTUM-First Study Group. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","unstructured":"Erba HP,\nMontesinos P,\nKim HJ, et al.; on behalf of the QuANTUM-First Study Group. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10388):1571\u20131583."},{"key":"i1543-2165-150-3-235-b04","article-title":"VANFLYTA\u00ae first FLT3 inhibitor approved in the U.S. specifically for patients with newly diagnosed FLT3-ITD positive AML [press release]","author":"Daiichi Sankyo","year":"2023","unstructured":"Daiichi Sankyo. VANFLYTA\u00ae first FLT3 inhibitor approved in the U.S. specifically for patients with newly diagnosed FLT3-ITD positive AML [press release]. https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202307\/20230720_E.pdf. Published July 20, 2023. Accessed July 31, 2023."},{"key":"i1543-2165-150-3-235-b05","article-title":"VANFLYTA\u00ae (quizartinib) [package insert]","year":"2024","unstructured":"VANFLYTA\u00ae (quizartinib) [package insert]. Daiichi Sankyo, Inc. https:\/\/daiichisankyo.us\/prescribing-information-portlet\/getPIContent?productName=Vanflyta&inline=true. Published June 2024. Accessed August 8, 2025."},{"key":"i1543-2165-150-3-235-b06","article-title":"VANFLYTA\u00ae first FLT3 inhibitor approved in Japan for patients with newly diagnosed FLT3-ITD positive AML [press release]","author":"Daiichi Sankyo.","year":"2023","unstructured":"Daiichi Sankyo.VANFLYTA\u00ae first FLT3 inhibitor approved in Japan for patients with newly diagnosed FLT3-ITD positive AML [press release]. https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202305\/20230525_E.pdf. Published May 25, 2023. Accessed June 13, 2023."},{"key":"i1543-2165-150-3-235-b07","article-title":"VANFLYTA\u00ae approved in the EU as the first FLT3 inhibitor specifically for patients with newly diagnosed FLT3-ITD positive AML [press release]","author":"Daiichi Sankyo.","year":"2023","unstructured":"Daiichi Sankyo. VANFLYTA\u00ae approved in the EU as the first FLT3 inhibitor specifically for patients with newly diagnosed FLT3-ITD positive AML [press release]. https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202311\/20231109_E.pdf. Published November 9, 2023. Accessed November 9, 2023."},{"key":"i1543-2165-150-3-235-b08","article-title":"VANFLYTA\u00ae (quizartinib) summary of product characteristics","year":"2023","unstructured":"VANFLYTA\u00ae (quizartinib) summary of product characteristics. Daiichi Sankyo Europe GmbH. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vanflyta-epar-product-information_en.pdf. Published November 2023. Accessed November 9, 2023."},{"key":"i1543-2165-150-3-235-b09","article-title":"Quizartinib approved to treat adult patients with a type of blood cancer","author":"Medicines and Healthcare Products Regulatory Agency.","year":"2024","unstructured":"Medicines and Healthcare Products Regulatory Agency. Quizartinib approved to treat adult patients with a type of blood cancer [press release]. https:\/\/www.gov.uk\/government\/news\/quizartinib-approved-to-treat-adult-patients-with-a-type-of-blood-cancer. Published March 11, 2024. Accessed May 24, 2024."},{"key":"i1543-2165-150-3-235-b10","article-title":"VANFLYTA\u00ae (quizartinib) summary of product characteristics","year":"2024","unstructured":"VANFLYTA\u00ae (quizartinib) summary of product characteristics. Daiichi Sankyo UK Ltd. https:\/\/products.mhra.gov.uk\/substance\/?substance=QUIZARTINIB%20DIHYDROCHLORIDE. Published March 2024. Accessed May 24, 2024."},{"key":"i1543-2165-150-3-235-b11","article-title":"VANFLYTA\u00ae, Filmtabletten (Quizartinibum)","author":"Swiss Agency for Therapeutic Products, Swissmedic.","year":"2025","unstructured":"Swiss Agency for Therapeutic Products, Swissmedic. VANFLYTA\u00ae, Filmtabletten (Quizartinibum). https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/humanarzneimittel\/authorisations\/new-medicines\/vanflyta-filmtabletten-quizartinibum.html. Published March 31, 2025. Accessed April 24, 2025."},{"key":"i1543-2165-150-3-235-b12","article-title":"Invivoscribe announces FDA approval of the LeukoStrat\u00ae CDx FLT3 Mutation Assay to select patients with FLT3-ITD positive AML for treatment with VANFLYTA\u00ae","author":"Invivoscribe","year":"2023","unstructured":"Invivoscribe. Invivoscribe announces FDA approval of the LeukoStrat\u00ae CDx FLT3 Mutation Assay to select patients with FLT3-ITD positive AML for treatment with VANFLYTA\u00ae [press release]. https:\/\/invivoscribe.com\/invivoscribe-announces-fda-approval-of-the-leukostrat-cdx-flt3-mutation-assay-to-select-patients-with-flt3-itd-positive-aml-for-treatment-with-vanflyta\/. Published July 21, 2023. Accessed October 12, 2023."},{"key":"i1543-2165-150-3-235-b13","article-title":"Invivoscribe announces updated reimbursement for the LeukoStrat CDx FLT3 Mutation Assay\u00ae to select newly diagnosed FLT3-ITD positive AML patients eligible for VANFLYTA\u00ae in Japan [press release]","author":"Invivoscribe","year":"2023","unstructured":"Invivoscribe. Invivoscribe announces updated reimbursement for the LeukoStrat CDx FLT3 Mutation Assay\u00ae to select newly diagnosed FLT3-ITD positive AML patients eligible for VANFLYTA\u00ae in Japan [press release]. https:\/\/invivoscribe.com\/invivoscribe-announces-updated-reimbursement-for-the-leukostrat-cdx-flt3-mutation-assay-to-select-newly-diagnosed-flt3-itd-positive-aml-patients-eligible-for-vanflyta-in-japan\/. Published May 25, 2023. Accessed October 12, 2023."},{"key":"i1543-2165-150-3-235-b14","article-title":"EU notified body (BSI Netherlands) and the EMA grant approval of the LeukoStrat\u00ae CDx FLT3 Mutation Assay for VANFLYTA\u00ae therapy in the EU and EEA [press release]","author":"Invivoscribe","year":"2024","unstructured":"Invivoscribe. EU notified body (BSI Netherlands) and the EMA grant approval of the LeukoStrat\u00ae CDx FLT3 Mutation Assay for VANFLYTA\u00ae therapy in the EU and EEA [press release]. https:\/\/invivoscribe.com\/eu-notified-body-bsi-netherlands-and-the-ema-grant-approval-of-the-leukostrat-cdx-flt3-mutation-assay-for-vanflyta-therapy-in-the-eu-and-eea\/. Published October 8, 2024. Accessed October 25, 2024."},{"key":"i1543-2165-150-3-235-b15","article-title":"Invivoscribe announces registration of the LeukoStrat\u00ae CDx FLT3 Mutation Assay in the United Kingdom and Switzerland [press release]","author":"Invivoscribe","year":"2025","unstructured":"Invivoscribe. Invivoscribe announces registration of the LeukoStrat\u00ae CDx FLT3 Mutation Assay in the United Kingdom and Switzerland [press release]. https:\/\/invivoscribe.com\/invivoscribe-announces-registration-of-the-leukostrat-cdx-flt3-mutation-assay-in-the-united-kingdom-and-switzerland\/. Published March 27, 2025. Accessed April 24, 2025."},{"key":"i1543-2165-150-3-235-b16","article-title":"The LeukoStrat\u00ae CDx FLT3 Mutation Assay","author":"Invivoscribe","unstructured":"Invivoscribe. The LeukoStrat\u00ae CDx FLT3 Mutation Assay. https:\/\/invivoscribe.com\/products\/companion-diagnostics-cdx\/. Accessed December 6, 2023."},{"issue":"11","key":"i1543-2165-150-3-235-b17","series-title":"Oncotarget","first-page":"943","article-title":"Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells","volume":"11","author":"Aikawa","year":"2020","unstructured":"Aikawa T,\nTogashi N,\nIwanaga K, et al. Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells. Oncotarget. 2020;11(11):943\u2013955."},{"issue":"7","key":"i1543-2165-150-3-235-b18","series-title":"Blood","first-page":"1425","article-title":"FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML","volume":"115","author":"Pratz","year":"2010","unstructured":"Pratz KW,\nSato T,\nMurphy KM,\nStine A,\nRajkhowa T,\nLevis M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood. 2010;115(7):1425\u20131432."},{"issue":"14","key":"i1543-2165-150-3-235-b19","series-title":"Blood","first-page":"2984","article-title":"AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)","volume":"114","author":"Zarrinkar","year":"2009","unstructured":"Zarrinkar PP,\nGunawardane RN,\nCramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114(14):2984\u20132992."},{"issue":"4","key":"i1543-2165-150-3-235-b20","series-title":"PLoS One","first-page":"e0121177","article-title":"Crystal structure of the FLT3 kinase domain bound to the inhibitor quizartinib (AC220)","volume":"10","author":"Zorn","year":"2015","unstructured":"Zorn JA,\nWang Q,\nFujimura E,\nBarros T,\nKuriyan J. Crystal structure of the FLT3 kinase domain bound to the inhibitor quizartinib (AC220). PLoS One. 2015;10(4):e0121177."},{"issue":"2","key":"i1543-2165-150-3-235-b21","series-title":"J Mol Diagn","first-page":"96","article-title":"Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay","volume":"5","author":"Murphy","year":"2003","unstructured":"Murphy KM,\nLevis M,\nHafez MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. 2003;5(2):96\u2013102."},{"key":"i1543-2165-150-3-235-b22","article-title":"Japan\u2019s MHLW approves Invivoscribe\u2019s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo\u2019s quizartinib for treatment of relapsed\/refractory FLT3-ITD AML: expands use to include specimens collected in EDTA [press release]","author":"Invivoscribe","year":"2019","unstructured":"Invivoscribe. Japan\u2019s MHLW approves Invivoscribe\u2019s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo\u2019s quizartinib for treatment of relapsed\/refractory FLT3-ITD AML: expands use to include specimens collected in EDTA [press release]. https:\/\/invivoscribe.com\/japans-mhlw-approves-invivoscribes-leukostrat-cdx-flt3-mutation-assay-as-the-cdx-for-daiichi-sankyos-quizartinib-for-treatment-of-relapsed-refractory-flt3-itd-aml-expands\/. Published June 19, 2019. Accessed October 12, 2023."},{"issue":"3","key":"i1543-2165-150-3-235-b23","series-title":"R I Med J (2013)","first-page":"38","article-title":"Acute myeloid leukemia: a review","volume":"103","author":"Pelcovits","year":"2020","unstructured":"Pelcovits A,\nNiroula R. Acute myeloid leukemia: a review. R I Med J (2013). 2020;103(3):38\u201340."},{"issue":"9","key":"i1543-2165-150-3-235-b24","series-title":"Cureus","first-page":"e45765","article-title":"FLT3 mutations in acute myeloid leukemia: unraveling the molecular mechanisms and implications for targeted therapies","volume":"15","author":"Jalte","year":"2023","unstructured":"Jalte M,\nAbbassi M,\nEl Mouhi H,\nDaha Belghiti H,\nAhakoud M,\nBekkari H. FLT3 mutations in acute myeloid leukemia: unraveling the molecular mechanisms and implications for targeted therapies. Cureus. 2023;15(9):e45765."},{"key":"i1543-2165-150-3-235-b25","article-title":"ISO 20916:2019: in vitro diagnostic medical devices\u2014clinical performance studies using specimens from human subjects\u2014good study practice","author":"International Organization for Standardization","unstructured":"International Organization for Standardization. ISO 20916:2019: in vitro diagnostic medical devices\u2014clinical performance studies using specimens from human subjects\u2014good study practice. https:\/\/www.iso.org\/standard\/69455.html. Accessed August 8, 2025."},{"key":"i1543-2165-150-3-235-b26","article-title":"ICH E6(R3): Guideline for good clinical practice","author":"International Council for Harmonisation","unstructured":"International Council for Harmonisation. ICH E6(R3): Guideline for good clinical practice. https:\/\/database.ich.org\/sites\/default\/files\/ICH_E6(R3)_Step4_FinalGuideline_2025_0106.pdf. Published January 6, 2025. Accessed August 8, 2025."}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/150\/3\/article-p235.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/doi\/10.5858\/arpa.2024-0449-OA\/3538839\/10.5858_arpa.2024-0449-oa.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/150\/3\/article-p235.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/150\/3\/article-p235.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T03:28:08Z","timestamp":1772076488000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/150\/3\/article-p235.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":52,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.5858\/arpa.2024-0449-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}